Zimmer Biomet Holdings Inc (ZBH)
Valor JustoFundamental
63
Precio
$88.83
Capitalización Bursátil
$17.48B
Parte 1 · Cuánto vale la empresa
Resumen
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open-heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, healthcare institutions, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. It also offers ROSA Robot, which utilizes robotic technologies to assist a surgeon with implant positioning in total knee arthroplasty or partial knee arthroplasty; and the ZBEdge Platform connects robotic and digital technologies together to collect data before, during and after surgery, that can deliver insights to surgeons to assist in making informed decisions on patient care. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance y Liquidez
Ingresos
$8.51B
Últimos 12 meses (hasta 30/6/2026)
Beneficio Neto
$807M
Últimos 12 meses (hasta 30/6/2026)
Flujo de Caja Libre
$1.47B
Patrimonio Neto Total
$12.70B
Pasivo Total
$10.39B
Ratio de Liquidez
1.69
Cobertura de Intereses
4.17
Deuda/EBITDA
3.41
Beneficio Por Acción
Ingresos y Beneficio Neto
Flujo de Caja Libre
Desglose de Ingresos
Estado histórico
Márgenes en el tiempo
La deuda en el tiempo
Cuánto pesa la deuda
Cuadro de crecimiento
Crecimiento — Ingresos
Estimación de Valor Justo
Valor Justo
$110.62
Precio Actual
$88.83
Margen de Seguridad
+19.7%
Rango de Valor Justo
$71.91 - $149.34
Dispersión entre los métodos de valoración utilizados, no un intervalo de confianza calibrado estadísticamente.
Métodos de Estimación
Métricas de Valoración
Ratio P/E
21.56
ROE
5.6%
Ratio P/B
1.34
P/FCF
11.12
Margen Bruto
69.9%
ROIC
4.8%
Radar de Rentabilidad
Creación de Valor (Ventaja Competitiva)
ROIC
4.8%
WACC
6.5%
ROIC − WACC
-1.7 pp
El ROIC está por debajo del coste del capital: la empresa destruye valor por cada dólar invertido.
Criterios de Análisis Fundamental
Superado (16)
- EPS shows upward trend
- Gross Margin 69.9%
- P/FCF 11.12
- P/B Ratio 1.34
- Debt/Equity ratio
- Operating Margin 14.2%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Earnings Surprise avg 3.4%
- Earnings Quality (OCF/NI) 2.16
- Share Dilution -2.6%
- Piotroski F-Score 5/9
Fallido (10)
- EPS CAGR 0.47%
- Price CAGR -0.69%
- ROIC 4.8%
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Fairly valued)
- ROE 6.3%
- Revenue Growth 5Y 3.2%
- Analyst Consensus 33% Buy
- Net Margin Trend 9.5% vs 10.5%
No disponible (2)
- Dividend Payout NaN%
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
Señales mixtas: algunas áreas requieren atención
Calidad de los Beneficios
Alta calidad: beneficios respaldados por efectivo
Dilución de Acciones
Recomprando acciones. Favorable para el accionista
Participaciones institucionales
Gobernanza
Equipo Directivo
| Nombre | Cargo | Edad |
|---|---|---|
| Mr. Ivan Tornos | President, CEO & Chairman of the Board | 50 |
| Mr. Wilfred van Zuilen | Group President of Europe, Middle East & Africa | 55 |
| Mr. JehanZeb Noor | Senior VP, Chief Strategy, Business Development, Innovation & Transformation Officer | 43 |
| Mr. Kevin R. Thornal | Group President of Global Businesses & Americas | 51 |
| Mr. Paul A. Stellato | Interim CFO, VP, Controller & Chief Accounting Officer | 50 |
| Mr. Shaun Braun | Senior VP & Chief Information and Technology Officer | - |
| Dr. Jonathan M. Vigdorchik M.D. | Chief Science, Technology & Medical Affairs Officer | - |
| Mr. David M. DeMartino | Senior Vice President of Investor Relations | - |
| Mr. Chad F. Phipps J.D. | Senior VP, Chief Legal & Corporate Affairs Officer and Secretary | 53 |
| Ms. Angela Main | Senior VP, Global Chief Compliance Officer & Associate General Counsel of Asia Pacific | - |
Riesgo de Auditoría
6
Riesgo del Consejo
8
Riesgo de Compensación
8
Riesgo de Derechos del Accionista
4
Parte 2 · El precio y el momento de entrar
Esta parte no sirve para saber si la empresa vale: sirve para elegir cuándo comprarla, una vez que los fundamentales te han convencido. Dentro: análisis técnico, potencial, caídas históricas, exposición gamma.
Documentos
- Ver documento
Informe anual (10-K)
Un resumen anual del negocio, los resultados financieros y los riesgos de la empresa.
Presentado el 2026-02-20
- Ver documento
Informe trimestral (10-Q)
Una actualización del desempeño financiero de los últimos tres meses.
Presentado el 2026-08-05
- Ver documento
Informe de hecho relevante (8-K)
Un aviso sobre un hecho relevante, como un cambio de dirección o un anuncio importante.
Presentado el 2026-09-08
via SEC EDGAR
Historial de Resultados
via SEC EDGAR
Latest News
Recent headlines for ZBH, sourced from Markets Gazette.